News Focus
News Focus
icon url

motorcity

05/03/21 8:34 AM

#72461 RE: sleuth100 #72460

sleuth, as always thank you for your diligence.

I agree there should be another PR for this.

THey were putting out a ton of frivolous PR's for a long time, now they put out nothing for long stretches. Another area where there is easy opportunity for improvement if they choose to make it.

If there's a silver lining its that while they continue to look good on the product itself there's major inroads and opportunity for sales, marketing and PR to improve.
icon url

SpaceLady

05/03/21 6:03 PM

#72466 RE: sleuth100 #72460

I think they will do a PR once they receive official notification.
icon url

Wolf-man jack

07/22/21 3:32 AM

#73095 RE: sleuth100 #72460

Say Hello to New Harvest and good riddance to Chantix YQU Understand. Have Mercy Wolf Ahooooooo

By the way if YQU recall, no pun intended YQU Understand. JOsE mentioned that the reason they couldn’t get their Authorized Shares increase was because the majority of shareholders are retailers such as myself YQU Understand. The WQLF has quietly in the past week, Increased shares of over 26,000 during our Blue Light Special shining its ever lasting Light on YQU.

Smooth Move is correct that there is a gap and the short people will panic and have to cover at a higher SP YQU surely understand.

The timing of New Harvest info by our fine and excellent management has come at a very coincidental moment in time.

Dr. Joong J. Fang Said: YQU Better YQU Bet.

https://www.newsweek.com/pfizer-recalls-several-lots-chantix-increased-cancer-risks-1611233

WQLF Says: Of course the FDA would say that YQU Understand. Have Mercy Wolf Ahooooooo

“ the FDA said in a release. The statement also explained that the health benefits of quitting smoking would likely outweigh the potential damages from ingesting the increased levels of N-nitroso-varenicline.”

icon url

Wolf-man jack

07/22/21 6:28 AM

#73101 RE: sleuth100 #72460

SLEUTH SAID;

“ In addition to the European patent office intentions to approve the cv-007 patent this initial publication of a cv-007 study in the european journal Psychopharmacology should be another PR.

https://link.springer.com/article/10.1007/s00213-021-05845-4

Funding suggest that money is available for cvsi to pursue this program.

"This work was supported by the National Institute on Drug Abuse (grant no. 1F31DA047113-01 to L.C.S.), National Institute on Alcohol Abuse and Alcoholism (grant no. AA022977 and AA006420 to O.G.), Tobacco-Related Disease Research Program (grant no. 27IR-0047 to O.G.), Tobacco-Related Disease Research Program (grant no. T31KT1859 to M.K.), and CV science (O.G.)."